You are here


Mandatory notification of trade

23 July 2008: Nancy Murphy, President of NorDiag Inc. and primary insider in NorDiag ASA, purchased on Monday 21 July 10.000 shares in NorDiag ASA at a price per share of USD 0.395. On Tuesday 22 July, Murphy bought 40.000 additional shares at a price of USD 0.410 per share. Murphy did not own any shares in NorDiag ASA before these two transactions and thus currently holds 50.000 shares. In addition, Murphy holds 300.000 share options.

CEO Mårten Wigstøl
Phone: +47 911 65775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing of automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections.

The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall  contribute to early diagnosis of colorectal cancer, as well as a test that shall contribute to optimal treatment of lung cancer patients. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 34 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD.

For further information -

Read the Notice on Oslo Stock Exchange's Newsweb here

Read the Notice in Norwegian here